Kilitch Healthcare India Limited issues voluntary recall of various eye drops due to potential safety risk


The recall is “due to potential safety concerns after FDA investigators found insanitary conditions.”

©Piman Khrutmuang –

Image credit: ©Piman Khrutmuang –

Kilitch Healthcare India Limited has issued a voluntary recall for over 20 brands of eye drops at the consumer level, according to a press release from the company released on the FDA website.1

According to Kilitch Healthcare India Limited, the recall is “due to potential safety concerns after FDA investigators found insanitary conditions.”1

The company stated that anyone who used the eyedrops listed in the recall faces a potential risk of eye infections or related harm. Kilitch Healthcare India Limited has not received any reports of adverse events related to this recall.

Products affected in this recall can be found on

The FDA recently issued a warning letter to Amazon over selling unapproved eye care products, as well as urged customers to avoid certain eye drops due to risk of infections.

The eye drops were distributed nationwide to wholesalers, retailers, and via the product distributor, Velocity Pharma LLC. Furthermore, according to Kilitch Healthcare India Limited, the company is notifying the distributor who will arrange for the return of all affected items.

  1. Kilitch Healthcare India Limited Issues Voluntary Nationwide Recall of Various Eye Drops for Potential Safety Reasons. Press Release. Released November 15, 2023. Accessed November 16, 2023.
Related Videos
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
TENAYA, LUCERNE year 2 data reveals promising results for faricimab
How to diagnose geographic atrophy earlier
World Sight Day 2022: Eye care professionals share what global vision means to them
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
Understanding fluid dynamics in wet macular degeneration
YOSEMITE, RHINE treat-and-extend data show favorable results for faricimab for the treatment of DME
What are you most excited about in the field of retina? Tunde Peto, MD, PhD weighs in
Leveraging noninvasive ophthalmic imaging for patients with Alzheimer disease and analyzing UK Biobank data
© 2024 MJH Life Sciences

All rights reserved.